Investigational drug · Phase 3
NVXC19
Also called: EU licensed, standalone
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Immunization, Healthy Volunteers, COVID-19 Immunization.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "NVXC19"
First trial start
2026
Oct 28, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NVXC19", any sponsor or status.
Conditions studied
As listed on its trial records.
- Immunization
- Healthy Volunteers
- COVID-19 Immunization
- Influenza Immunization
Approved drugs for the same conditions: COVID-19 · Influenza · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "NVXC19" as an intervention, largest first.
- Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and OlderPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07890454 · 6,000 participants (planned) · Start Oct 28, 2026 · Primary completion Dec 28, 2027
Drug: IIV-HD (standalone); NVXC19 (EU licensed, standalone) and 2 more · For: Immunization; Healthy Volunteers; COVID-19 Immunization and 1 more
Sites: Wroclaw, Poland; Gdynia, Poland
SanofiSanofi (SNY)
NCT06695130 · 980 participants · Start Nov 18, 2024 · Primary completion Apr 3, 2026
Drug: RIV (recombinant influenza vaccine); rC19 (dose 1) and 4 more · For: COVID-19 Immunization; Influenza Immunization
Sites: Phoenix, Arizona; Cerritos, California; Vista, California · 12 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Immunization
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.